From: Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]
Adverse event
Control
Group A
Group B
Deaths
7
5
10
Nosocomial infection
21
22
26
Heart rate and rhythm disorders
3
2
Thrombocytosis
1
-
Deep vein thrombosis
Central nervous system disorders (new ischaemic or haemorrhagic stroke)